Renamed Supernus, Inc. on November 2, 2026; now trades as SUPN. This page is the pre-merger Indivior standalone snapshot.
What they do
Our core products include the following approved treatments: • SUBLOCADE (buprenorphine extended-release monthly injection); and • SUBOXONE Film (buprenorphine and naloxone sublingual film); both of which are treatments for OUD. Product availability varies across the countries in which Indivior treatments are available, including in terms of dosage, strength and indication.
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Share structure
Common
118.0M
Pre-funded warrants
0.0M
Options
—
RSUs
—
Warrants
0.0M
Converts
12.0M
Conv preferred
0.0M
ESPP reserve
—
FDSO
130.0M
Cap table as of 2026-10-09.
Indivior closed its business combination with Supernus Pharmaceuticals on November 2, 2026 and was renamed Supernus, Inc. The combined company began trading on Nasdaq as SUPN on November 3, 2026, and legacy Supernus Pharmaceuticals was delisted. Legacy Indivior holders kept their shares and received a $1.0B special cash dividend (about $8.47 per share) funded by a new $650M term loan and $350M of combined cash. The share counts and cash on this page are Indivior standalone before the merger. The combined company's rebuilt figures are on the SUPN page.
Moderate to severe opioid use disorder (OUD)(Approved)
Status note Buprenorphine-based LAI; first long-acting buprenorphine-based injectable approved for moderate to severe OUD. 74% of net revenue in H1 2026.
SUBOXONE Film
Approved · ActiveModality: sublingual film
Target opioid receptor
Indications
Opioid dependence/OUD(Approved)
Status note Buprenorphine/naloxone sublingual film, FDA approved 2010.
INDV-2000
Phase 2 · Active
Target orexin-1 receptor
Indications
Moderate to severe OUD(Phase 2)
Status note Non-opioid treatment for moderate to severe OUD. First subject dosed Jun 2024 in Phase 2 proof-of-concept study (NCT06384157). Company decided not to advance INDV-2000 internally (Q2 2026).
INDV-6001
Phase 3 · Terminated
Target mu-opioid receptor
Status note Company decided to cease Phase 3 development of INDV-6001 (Q2 2026); restructuring initiated.
Status note Risperidone LAI approved 2018, launched 2019. Marketing and promotion discontinued Jul 2024 due to expected market changes making the product no longer financially viable.
OPVEE
Approved · Terminated
Target opioid receptor
Indications
Opioid overdose reversal(Approved)
Status note Sales and marketing support discontinued Q3 2025 (strategic decision); product still distributed upon request.
SUBUTEX Tablet
Approved · TerminatedModality: sublingual tablet
Target mu-opioid receptor
Indications
Opioid use disorder(Approved)
Status note U.S. distribution discontinued 2011.
SUBOXONE Tablet
Approved · TerminatedModality: sublingual tablet
Target opioid receptor
Indications
Opioid use disorder(Approved)
Status note U.S. distribution discontinued 2013.
Per-asset detail extracted from the 10-Q filed 2026-08-03. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
Fund
Shares
Q/Q change
% of portfolio
Filing
Deerfield Management
1,648,895
-1,448,895
0.71%
2026-08-14
Stonepine Capital
100,000
+100,000
3.12%
2026-08-17
Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.